Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | GDF-8 |
| Clinical data | |
| Other names | PF-06252616 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6366H9826N1690O2008S46 |
| Molar mass | 143639.22 g·mol−1 |
This drug was developed by Pfizer. Pfizer stopped development in 2018 after disappointing results in 2 human trials.[3]
References
edit- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association.
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- ^ https://www.pfizer.com/news/press-release/press-release-detail/pfizer_terminates_domagrozumab_pf_06252616_clinical_studies_for_the_treatment_of_duchenne_muscular_dystrophy [bare URL]
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |